doi: 10.5732/cjc.011.10377

Chemical proteomics: terra incognita for novel drug target profiling

Fuqiang Huang, Boya Zhang, Shengtao Zhou, Xia Zhao, Ce Bian, Yuquan Wei

The State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China

[Abstract] The growing demand for new therapeutic strategies in the medical and pharmaceutic fields has resulted in a pressing need for novel druggable targets. Paradoxically, however, the targets of certain drugs that are already widely used in clinical practice have largely not been annotated. Because the pharmacologic effects of a drug can only be appreciated when its interactions with cellular components are clearly delineated, an integrated deconvolution of drug-target interactions for each drug is necessary. The emerging field of chemical proteomics represents a powerful mass spectrometry (MS)-based affinity chromatography approach for identifying proteome-wide small molecule-protein interactions and mapping these interactions to signaling and metabolic pathways. This technique could comprehensively characterize drug targets, profile the toxicity of known drugs, and identify possible off-target activities. With the use of this technique, candidate drug molecules could be optimized, and predictable side effects might consequently be avoided. Herein, we provide a holistic overview of the major chemical proteomic approaches and highlight recent advances in this area as well as its potential applications in drug discovery.

Chinese Journal of Cancer 2012, Volume: 31, Issue 11, Page: 507-518

[ PDF Full-text ]
[ Html full-text ](PubMed Central)
[ PubMed ]
[Google Scholar]

Cite this article

Fuqiang Huang, Boya Zhang, Shengtao Zhou, Xia Zhao, Ce Bian, Yuquan Wei. Chemical proteomics: terra incognita for novel drug target profiling. Chin J Cancer. 2012, 31(11):507-518. doi:10.5732/cjc.011.10377


Export citations

EndNote